-
-
-
-
-
-
-
Teva Pharma (TEVA) PT Raised to $42 at UBS
-
-
-
-
-
-
-
Jefferies Reiterates Buy Rating on Teva Pharma (TEVA)
-
-
-
-
-
-
-
FDA accepts Teva's application for monthly schizophrenia injection
-
-
-
-
-
-
-
Teva Pharma (TEVA) PT Raised to $37 at BofA Securities
-
-
-
-
-
-
-
TEVA secures $500 million funding from Royalty Pharma for vitiligo drug
-
-
-
-
-
-
-
Scotiabank Starts Teva Pharma (TEVA) at Sector Outperform
-
-
-
-
-
-
-
Teva Pharma (TEVA) PT Raised to $26 at UBS, 2030 Sales Estimate Increased
-
423,328 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

